SILEXION THERAPEUTICS CORP Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
SILEXION THERAPEUTICS CORP (SLXN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 4.27 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- SILEXION THERAPEUTICS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 4.27K shares, a 93.92% decline year-over-year.
- SILEXION THERAPEUTICS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- SILEXION THERAPEUTICS CORP share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was -65.55K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − S-1/A 3 month · filed 2026-08-14 | 4.27K shares 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | 4.27K shares S-1/A · filed 2026-08-10 | 42.74K shares 10-Q · filed 2026-05-15 | ||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -65.55K shares derived: sum of 2 quarters · filed 2025-11-12 | 4.68K shares 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -65.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 4.68K shares 10-Q · filed 2025-08-12 | ||
| 2025-03-31 | 70.22K shares 10-Q · filed 2025-05-13 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |